Recombinant Neorudin for the Prevention of Deep-Vein Thrombosis After Spinal-Cord Injury

Drug Design, Development and Therapy, 2023 · DOI: https://doi.org/10.2147/DDDT.S408078 · Published: August 23, 2023

Spinal Cord Injury Cardiovascular Science Pharmacology

Simple Explanation

Deep-vein thrombosis (DVT) is a common early complication after spinal-cord injury (SCI) and spinal surgery, but it can also occur in the chronic period. The anticoagulant effect of EH is blocked totally by EPR, which can be identified and cleaved by coagulation factor Xa (FXa) and/or coagulation factor XIa (FXIa). In the present study, the effects of EH on thrombus inhibition and safety were evaluated in a rat model of SCI complicated with venous thrombosis.

Study Duration

Not specified

Participants

Male Sprague–Dawley rats (260 g)

Evidence Level

Not specified

Key Findings

1
EH inhibited thrombosis in a dose-dependent manner by reducing the wet weight and dry weight of the thrombus.
2
EH administration after SCI neither increased bleeding in the injured spine nor damaged to nerve function.
3
EH can reduce thrombus formation in a rat model of SCI, and bleeding is decreased significantly compared with that using LMWH.

Research Summary

EH inhibited thrombosis after SCI in a dose-dependent manner. Application of EH did not increase bleeding in the injured SC or damage nerve function. EH may provide a safe and effective anticoagulant drug choice for patients with SCI.

Practical Implications

Thrombus Prevention

Recombinant neorudin (EH) can be used to effectively prevent deep vein thrombosis (DVT) following spinal cord injury (SCI) or spinal surgery.

Reduced Bleeding Risk

EH presents a lower risk of bleeding compared to low molecular weight heparin (LMWH), making it a safer option for anticoagulation in SCI patients.

Early Treatment

Initiating EH therapy within 6 hours after SCI may be more effective in reducing thrombus size.

Study Limitations

1
Study performed on a rat model, results may not directly translate to humans.
2
Further research is needed before EH is accepted to perform clinical trials in SCI patients.
3
Consensus regarding the time to start thromboprophylaxis using anticoagulants after injury or surgery is lacking.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury